BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For example, in the sentence “Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML),” “Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor” can already express the inhibitory relationship between the entities “Dasatinib” and “SRC.” Other words, which may affect the performance of the relation extractor, are irrelevant.